Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177784 | SCV000229715 | uncertain significance | not provided | 2014-10-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000795712 | SCV000935182 | likely benign | Nemaline myopathy 2 | 2024-08-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002516754 | SCV003736697 | uncertain significance | Inborn genetic diseases | 2022-07-27 | criteria provided, single submitter | clinical testing | The c.3721G>T (p.V1241L) alteration is located in exon 34 (coding exon 32) of the NEB gene. This alteration results from a G to T substitution at nucleotide position 3721, causing the valine (V) at amino acid position 1241 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000177784 | SCV005690351 | uncertain significance | not provided | 2024-08-07 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV000795712 | SCV002077731 | uncertain significance | Nemaline myopathy 2 | 2019-11-11 | no assertion criteria provided | clinical testing |